Compare AbbVie Inc (ABBV) vs Oklo Inc (OKLO) Price & Performance

AbbVie (ABBV) trades at $247.91, up 0.76% on the day, with strong technical momentum as the stock approaches resistance near $249. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $3.65 versus $3.61, driven by robust immunology portfolio growth from Skyrizi and Rinvoq offsetting Humira declines. Revenue reached $61.16B in 2025 with a 71.48% gross margin, though net income margin compressed to 9.8%. Recent positive Phase 2 ovarian cancer data and institutional accumulation signal confidence in the pipeline.

Outlook remains positive with analyst consensus target of $281.33 (13.5% upside) and 71% buy ratings, though elevated P/E of 70.05 reflects growth expectations. Key risks include patent cliffs in the 2030s, competitive pressures, and regulatory uncertainties from drug pricing lawsuits. The dividend aristocrat offers income stability with recent $1.73 payout, but investors should monitor execution of oncology pipeline and debt levels at 50.4% of assets.

OKLO trades at $48.42, up 14.77% in the past 24 hours, with a bullish technical signal and strong analyst consensus. The stock is supported by recent milestones, including the Groves reactor achieving first criticality and reporting its first meaningful revenue of $1.2 million in Q2 2026, though it posted a wider net loss. The company maintains substantial liquidity of approximately $2.5 billion as of March 2026, supporting its aggressive development plans.

The outlook is optimistic due to strong institutional backing and growth potential in the nuclear energy sector, but significant execution risks and persistent losses pose challenges. The consensus price target of $82.69 suggests substantial upside if operational milestones are met, yet the high cash burn and unproven business model warrant caution for investors.